Merck IL-29 human

IL-29 human

recombinant, expressed in E. coli, ≥90% (SDS-PAGE), ≥90% (HPLC)

IFN-λ 1, Interleukin-29, Cytokine ZCYTO21, IL29, Interferon-λ 1

생물학적 소스

human

재조합

expressed in E. coli

assay

≥90% (HPLC)
≥90% (SDS-PAGE)

form

lyophilized

분자량

~20 kDa

포장

pkg of 20 μg

불순물

endotoxin, tested

NCBI 수납 번호

Q8IU54

배송 상태

wet ice

저장 온도

−20°C

Gene Information

human ... IL29(282618)

IL-29 is distantly related to type I interferons and the IL-10 family. Expression of IL-29 is induced by viral infection which interacts with a heterodimeric class II cytokine receptor that consists of interleukin 10 receptor beta (IL10RB) and interleukin 28 receptor alpha. IL-29 exhibits common features with type I IFNs such as antiviral activity, antiproliferative activity and in vivo antitumour activity. IL-29 acts similarly to IFNs, but is less effective generally and has activity in a more limited range of cell lines. IL-29 produced in response to viral infection, activates both monocytes and macrophages producing a restricted panel of cytokines and therefore is an important factor in activating innate immune responses at the site of viral infection. IFN-λ 1 antiviral and antiproliferative activity requires Interferon-λ 2 receptor tyrosine residues. Recombinant human IL-29 produced in E. coli is a single, non-glycosylated, polypeptide chain containing 181 amino acids and having a molecular mass of 20 kDa.